Holen Sie sich die Stockscreener-App
38.54
4.22%
-1.76
Schlusskurs vom Vortag:
$40.30
Offen:
$39.99
24-Stunden-Volumen:
1.66M
Relative Volume:
0.55
Marktkapitalisierung:
$5.92B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-284.08M
KGV:
-15.90
EPS:
-2.4234
Netto-Cashflow:
$-234.65M
1W Leistung:
-0.98%
1M Leistung:
+160.45%
6M Leistung:
+459.39%
1J Leistung:
+299.15%
1-Tages-Spanne:
$38.16
$40.43
1-Wochen-Bereich:
$37.94
$43.73
52-Wochen-Spanne:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Vergleichen Sie COGT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
38.58 | 6.19B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.06 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.57 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-10 | Hochstufung | Stifel | Hold → Buy |
| 2025-11-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-10-16 | Eingeleitet | Stifel | Hold |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-11 | Herabstufung | Needham | Buy → Hold |
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences Presents Positive Clinical Trial Results - TradingView
Cogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wedbush Adjusts Cogent Biosciences Price Target to $55 From $38, Maintains Outperform Rating - marketscreener.com
Cogent Biosciences Says Bezuclastinib Showed 'Rapid and Deep Clinical Benefit' in Advanced Systemic Mastocytosis Trial - marketscreener.com
Cogent Biosciences stock hits all-time high at 43.07 USD - Investing.com
Cogent Biosciences : COGT ASH 2025 Webcast FINAL - marketscreener.com
Cogent Biosciences (COGT) Reports Positive Results from APEX Par - GuruFocus
Cogent Biosciences announces positive top-line results of apex trial of bezuclastinib in patients with advanced systemic mastocytosis - marketscreener.com
Cogent Biosciences Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis - TradingView
Cogent Biosciences, Inc. Announces Positive Top-Line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Schroder Investment Management Group Invests $896,000 in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences' (COGT) Bezuclastinib Shows Promising Results in Clinical Trial - GuruFocus
Cogent Biosciences, Inc. $COGT Shares Purchased by Kennedy Capital Management LLC - MarketBeat
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis at the 67th Annual Meeting of the American Society of Hematology - Investing News Network
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - The Manila Times
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - GlobeNewswire Inc.
Tema Etfs LLC Has $845,000 Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
Cogent Biosciences, Inc. $COGT is Saturn V Capital Management LP's 5th Largest Position - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cogent Biosciences Earnings Notes - Trefis
Is Cogent Biosciences Inc a good long term investmentREITs Market Trends & Free Exceptional ROI Methods - earlytimes.in
Can Cogent Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Technicals & High Conviction Buy Zone Alerts - Newser
Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT) - MarketBeat
XTX Topco Ltd Has $836,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Has $94,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Price Target Increased by 93.94% to 43.52 - MSN
Geode Capital Management LLC Raises Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
F m Investments LLC Takes Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Ensign Peak Advisors Inc Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences stock hits 52-week high at 40.76 USD By Investing.com - Investing.com Nigeria
Cogent Biosciences stock hits 52-week high at 40.76 USD - Investing.com
A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results - Sahm
Cogent Biosciences (NASDAQ:COGT) Reaches New 52-Week HighWhat's Next? - MarketBeat
Biotech Star Cogent Rides High On Breakthrough Trial Hopes - Finimize
Cogent Biosciences Announces $230 Million Convertible Senior Notes Offering - Global Legal Chronicle
Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance
Cogent Biosciences Completes $345 Million Common Stock Offering and $200 Million Convertible Notes Offering - Global Legal Chronicle
Top Biotech Stocks To ConsiderNovember 20th - MarketBeat
Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Finviz
Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Insider Monkey
10 Hottest SMID-Cap Stocks So Far In 2025 - Insider Monkey
Cogent Biosciences (NASDAQ:COGT) Sets New 12-Month HighStill a Buy? - MarketBeat
Technical Reactions to COGT Trends in Macro Strategies - news.stocktradersdaily.com
Mintz Advises on Cogent Biosciences Inc.’s Concurrent Public Offerings of $345 Million of Common Stock and $230 Million in Aggregate Principal Amount of 1.625% Convertible Senior Notes Due 2031 - Mintz
Cogent Biosciences stock hits 52-week high at 36.31 USD By Investing.com - Investing.com Canada
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):